CJC-1295 + Ipamorelin

CJC-1295 without DAC and Ipamorelin are synthetic research peptides that have been studied for their interactions with growth hormone-related signaling pathways. CJC-1295 without DAC is a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist.

This combination has been explored in preclinical and laboratory research as a model for studying complementary signaling mechanisms involved in endocrine regulation.

Research Overview

Published and preclinical research involving CJC-1295-related compounds and Ipamorelin has explored areas including:

• Growth hormone-releasing hormone receptor activity
• Growth hormone secretagogue receptor signaling
• Pulsatile growth hormone signaling models
• IGF-1-related pathways
• Endocrine and metabolic signaling
• Body-composition and energy-balance research models
• Cellular and tissue-response pathways

CJC-1295 without DAC and Ipamorelin remain investigational research compounds. Findings from laboratory, cellular, animal, or early-stage research should not be interpreted as demonstrating safety, effectiveness, or therapeutic benefit in humans.